HC Wainwright Reiterates “Buy” Rating for Axovant Sciences (AXON)

Axovant Sciences (NASDAQ:AXON)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday. They currently have a $11.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 103.70% from the company’s previous close.

A number of other research analysts have also recently commented on the company. Oppenheimer cut Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 26th. BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Evercore ISI reiterated an “outperform” rating and issued a $9.00 price objective (down from $30.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Piper Jaffray Companies cut Axovant Sciences from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $32.00 to $9.00 in a report on Tuesday, September 26th. Finally, UBS cut Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $14.13.

Axovant Sciences (NASDAQ AXON) opened at $5.40 on Friday. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its position in shares of Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 1,168 shares during the period. Bank of America Corp DE increased its holdings in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 2,789 shares during the last quarter. Voya Investment Management LLC purchased a new position in Axovant Sciences in the second quarter valued at $323,000. Finally, Laurion Capital Management LP purchased a new position in Axovant Sciences in the second quarter valued at $336,000. 96.93% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/12/03/hc-wainwright-reiterates-buy-rating-for-axovant-sciences-axon.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

What are top analysts saying about Axovant Sciences Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axovant Sciences Ltd. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit